Who is Yoshiaki Fujimori and why was he appointed to the Board?

Yoshiaki Fujimori is a new director appointed to Boston Scientific's Board of Directors. While the filing does not detail his specific background, his appointment to the Nominating and Governance Committee and the Finance Committee suggests the board is seeking to leverage his expertise in corporate governance and financial matters. The increase in board size indicates a strategic decision to expand the board's capacity.

What is the compensation for the new director, Mr. Fujimori?

Mr. Fujimori will receive compensation consistent with Boston Scientific's standard non-employee director program. This includes a prorated cash retainer of $73,019 and a prorated equity award valued at $150,094. The equity award will vest at the end of his term, and the number of shares will be determined on the grant date of August 1, 2016.

Does this appointment indicate any changes in the company's strategy or financial performance?

This 8-K filing focuses solely on a change in board composition. It does not provide any information regarding the company's strategy or financial performance. Such updates are typically covered in earnings releases, investor presentations, or other SEC filings like the Form 10-Q or 10-K.

Are there any other significant events reported in this 8-K?

No, this 8-K filing exclusively reports the appointment of Mr. Yoshiaki Fujimori to the Board of Directors and his committee assignments. It also includes a press release announcing this appointment as an exhibit.

BSX 8-K: Leadership Changes

Summary

Boston Scientific Corporation (BSX) filed an 8-K on July 13, 2016, to report a change in its Board of Directors. Effective July 13, 2016, the Board size was increased from ten to eleven directors with the appointment of Yoshiaki Fujimori. Mr. Fujimori, whose appointment fills a vacancy, will serve until the next annual meeting of stockholders. This appointment is a standard corporate governance update, indicating the board is seeking to maintain an optimal number of directors with diverse expertise. Investors should note that Mr. Fujimori brings additional governance and committee experience, having been appointed to serve on both the Nominating and Governance Committee and the Finance Committee. His compensation will follow the company's standard non-employee director program, including prorated cash retainers and equity awards.

Key Highlights

1Boston Scientific Corporation appointed Yoshiaki Fujimori as a new director to its Board of Directors, effective July 13, 2016.
2The Board of Directors' size was increased from ten to eleven directors to accommodate the new appointment.
3Mr. Fujimori will serve as a director until the company's 2017 annual meeting of stockholders.
4Mr. Fujimori has been appointed to serve on the Nominating and Governance Committee and the Finance Committee.
5The new director's compensation includes a prorated cash retainer and an equity award, consistent with the company's non-employee director compensation program.
6The appointment is effective immediately following the filing date, suggesting a strategic decision to enhance board capabilities.

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Jul 13, 2016)

Summary

Key Highlights

Frequently Asked Questions